Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $149,548 | 63 | 58.3% |
| Travel and Lodging | $46,753 | 103 | 18.2% |
| Consulting Fee | $41,953 | 26 | 16.4% |
| Food and Beverage | $15,967 | 359 | 6.2% |
| Education | $2,316 | 38 | 0.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Taiho Oncology, Inc. | $97,956 | 102 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $45,102 | 62 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $41,040 | 71 | $0 (2024) |
| Lilly USA, LLC | $24,833 | 56 | $0 (2022) |
| Celgene Corporation | $12,126 | 21 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $6,999 | 13 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $6,606 | 23 | $0 (2024) |
| Exelixis Inc. | $6,490 | 20 | $0 (2023) |
| Kite Pharma, Inc. | $3,894 | 4 | $0 (2019) |
| Bayer Healthcare Pharmaceuticals Inc. | $1,658 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,040 | 31 | AstraZeneca Pharmaceuticals LP ($3,264) |
| 2023 | $4,981 | 32 | Exelixis Inc. ($2,939) |
| 2022 | $29,372 | 78 | E.R. Squibb & Sons, L.L.C. ($26,371) |
| 2021 | $18,858 | 49 | Celgene Corporation ($11,276) |
| 2020 | $8,824 | 33 | Novartis Pharmaceuticals Corporation ($4,106) |
| 2019 | $72,064 | 126 | Taiho Oncology, Inc. ($36,244) |
| 2018 | $52,562 | 97 | Taiho Oncology, Inc. ($28,889) |
| 2017 | $64,835 | 143 | Taiho Oncology, Inc. ($29,611) |
All Payment Transactions
589 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Menarini Silicon Biosystems, Inc. | Cellsearch (Device) | Food and Beverage | Cash or cash equivalent | $19.35 | General |
| Category: Diagnostics | ||||||
| 12/04/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $122.31 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $134.98 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $5.41 | General |
| Category: Hematology | ||||||
| 11/13/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $109.38 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Menarini Silicon Biosystems, Inc. | Cellsearch (Device) | Food and Beverage | Cash or cash equivalent | $22.50 | General |
| Category: Diagnostics | ||||||
| 10/26/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $21.41 | General |
| 10/24/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $111.61 | General |
| 10/23/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $7.38 | General |
| Category: Hematology | ||||||
| 10/16/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $124.74 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 10/02/2024 | SEAGEN INC. | — | Education | In-kind items and services | $99.00 | General |
| 08/21/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $2.48 | General |
| Category: ONCOLOGY | ||||||
| 08/15/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $5.87 | General |
| Category: Oncology | ||||||
| 08/12/2024 | Myriad Genetic Laboratories, Inc. | MYRISK (Device) | Food and Beverage | In-kind items and services | $54.82 | General |
| Category: ONCOLOGY | ||||||
| 07/24/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $10.24 | General |
| Category: ONCOLOGY | ||||||
| 07/11/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $3.95 | General |
| Category: Hematology | ||||||
| 06/05/2024 | E.R. Squibb & Sons, L.L.C. | ONUREG (Drug) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Oncology | ||||||
| 05/22/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 05/08/2024 | PFIZER INC. | — | Education | In-kind items and services | $99.00 | General |
| 05/03/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.92 | General |
| Category: Oncology | ||||||
| 05/02/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Education | In-kind items and services | $99.00 | General |
| Category: Oncology | ||||||
| 04/29/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $2,497.50 | General |
| Category: Oncology | ||||||
| 04/24/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $124.00 | General |
| Category: Oncology | ||||||
| 04/24/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $4.96 | General |
| Category: ONCOLOGY | ||||||
| 04/22/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $4.09 | General |
| Category: Hematology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 497 | 873 | $383,474 | $77,252 |
| 2022 | 8 | 522 | 1,082 | $322,563 | $80,187 |
| 2021 | 10 | 507 | 1,093 | $219,328 | $74,573 |
| 2020 | 9 | 496 | 975 | $212,268 | $58,731 |
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 160 | 352 | $187,968 | $36,538 | 19.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 143 | 267 | $96,120 | $19,667 | 20.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 66 | 66 | $44,418 | $8,867 | 20.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 57 | 67 | $16,415 | $3,343 | 20.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 21 | 53 | $13,727 | $3,282 | 23.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 12 | 30 | $11,190 | $2,795 | 25.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 16 | 16 | $7,872 | $1,629 | 20.7% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2023 | 11 | 11 | $3,080 | $615.08 | 20.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2023 | 11 | 11 | $2,684 | $515.60 | 19.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 171 | 530 | $145,349 | $37,801 | 26.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 95 | 183 | $94,137 | $20,579 | 21.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 140 | 242 | $37,817 | $11,491 | 30.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 29 | 29 | $17,474 | $4,091 | 23.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 29 | 40 | $10,258 | $2,239 | 21.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 19 | 19 | $7,487 | $1,744 | 23.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 22 | 22 | $4,896 | $1,275 | 26.0% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2022 | 17 | 17 | $5,145 | $968.48 | 18.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 209 | 647 | $135,223 | $48,327 | 35.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 141 | 265 | $36,040 | $13,668 | 37.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 32 | 32 | $11,104 | $3,405 | 30.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 17 | 32 | $7,776 | $1,825 | 23.5% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Facility | 2021 | 27 | 27 | $5,508 | $1,770 | 32.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 14 | 14 | $7,182 | $1,511 | 21.0% |
| 38222 | Diagnostic aspirations and biopsies of bone marrow | Facility | 2021 | 23 | 25 | $7,875 | $1,424 | 18.1% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 20 | 24 | $3,264 | $1,301 | 39.9% |
About Dr. Ayodele Ayoola, M.D
Dr. Ayodele Ayoola, M.D is a Internal Medicine healthcare provider based in Hershey, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/26/2007. The National Provider Identifier (NPI) number assigned to this provider is 1164558763.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ayodele Ayoola, M.D has received a total of $256,536 in payments from pharmaceutical and medical device companies, with $5,040 received in 2024. These payments were reported across 589 transactions from 57 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($149,548).
As a Medicare-enrolled provider, Ayoola has provided services to 2,022 Medicare beneficiaries, totaling 4,023 services with total Medicare billing of $290,743. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Medical Oncology
- Location Hershey, PA
- Active Since 02/26/2007
- Last Updated 09/10/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1164558763
Products in Payments
- Lonsurf (Drug) $97,956
- KISQALI (Drug) $42,078
- CYRAMZA (Drug) $17,585
- EMPLICITI (Biological) $10,816
- Cabometyx (Drug) $3,540
- IMFINZI (Biological) $3,273
- CABOMETYX (Drug) $2,939
- CALQUENCE (Drug) $2,901
- PIQRAY (Drug) $2,850
- OPDIVO (Biological) $2,395
- ALIMTA (Drug) $2,215
- Aliqopa (Drug) $900.00
- Stivarga (Drug) $655.50
- JEVTANA (Drug) $510.85
- TECENTRIQ (Biological) $495.66
- Pomalyst (Drug) $381.69
- SIR-Spheres Microspheres (Device) $361.69
- Tavalisse (Drug) $317.27
- ADCETRIS (Biological) $307.38
- Kyprolis (Biological) $306.21
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Hershey
Shin Mineishi, Md, MD
Internal Medicine — Payments: $83,814
Dr. David Nguyen, Md, MD
Internal Medicine — Payments: $81,987
Dr. Sarah Hussain, Md, MD
Internal Medicine — Payments: $64,341
Mauricio Sendra Ferrer, M.d, M.D
Internal Medicine — Payments: $43,136
Dr. Michael Farbaniec, Md, MD
Internal Medicine — Payments: $20,179
Dr. Lauren Hollins, M.d, M.D
Internal Medicine — Payments: $19,304